

SB 289 A STAFF MEASURE SUMMARY

Carrier: Sen. Patterson

Senate Committee On Health Care

Action Date: 03/13/25

Action: Do pass with amendments. (Printed A-Eng.)

Vote: 5-0-0-0

Yeas: 5 - Campos, Hayden, Linthicum, Patterson, Reynolds

Fiscal: Has minimal fiscal impact

Revenue: No revenue impact

Prepared By: Daniel Dietz, LPRO Analyst

Meeting Dates: 3/6, 3/13

WHAT THE MEASURE DOES:

The measure allows Oregon's Prescription Drug Advisory Board (PDAB) to report annually instead of quarterly and to identify fewer than the nine drugs currently required for affordability review.

Detailed summary:

- Changes the requirement for the Department of Consumer and Business Services (DCBS) to produce a list of drugs exceeding certain price thresholds from each quarter to each year.
- Allows DCBS to identify up to nine drugs (instead of exactly nine) that may create affordability challenges.
- Directs the PDAB to report on the status of the generic drug market in its affordability report to the Health Care Cost Growth Target Program instead of making a separate report to the Legislative Assembly.

ISSUES DISCUSSED:

- Recommendations of the 2024 Prescription Drug Advisory Board report.

EFFECT OF AMENDMENT:

Replaces the measure.

BACKGROUND:

Oregon's Prescription Drug Advisory Board (PDAB) was established within the Department of Consumer and Business Services (DCBS) by Senate Bill 844 (2021). In its [2024 Annual Report](#), the PDAB recommended several “cleanup” changes to its reporting requirements (2024 Annual Report at p. 11).

Senate Bill 289 A allows the PDAB to report annually instead of quarterly, to identify fewer than nine drugs for affordability review, and to include reporting on generic drugs in the affordability review report.